menu search

Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL), on track for a Biologics License Application (BLA) submission to the US Food & Drug Administration (FDA) by end of 2023 Updated clinical data at the American Society of Hematology (ASH) meeting in December 2023: Long-term follow-up and sub-group analysis from […] The post Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates appeared fi... Read More
Posted: Nov 2 2023, 11:11
Author Name: forextv
Views: 112272

Search within

Pages Search Results: